Quality of life and pain before and after treatment with a fentanyl patch (relief - study)

Quality of life and pain before and after treatment with a fentanyl patch (relief - study) - Relief - Study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00011675

Enrollment

500

Registered

2017-01-31

Start date

2016-12-12

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

severe pain

Interventions

Group 1: fentanyl patch, transdermal, 12,5 - 100 µg/h

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: gender: male and female - age: at least 18 years - patient must be able to fill in the SF-12 (short Form 12) quality of life survey, patient has violent pain with indication for treatment with a strong opioid, such as transdermal Fentanyl patch, written informed consent

Exclusion criteria

Exclusion criteria: end stage disease with life expectancy < 6 months - prisoners or patients under disablity - pregnant or breastfeeding females - prolific women without contraception - alcohol or drug abusus - contraindication against fentanyl according to the prescribing Information - patients unable to consent

Design outcomes

Primary

Measure	Time frame
Quality of Life, measured by the Sf-12 (Short Form 12) before beginn of therapy and after 6 weeks	—

Secondary

Measure	Time frame
Pain and adhesion before and after 6 weeks of treatment with Fentanyl Draco Matrix® transdermal patch, additionally tolerance and side effects of Fentanyl Draco Matrix® transdermal patch within 6 weeks	—

Countries

Germany

Contacts

Public ContactTanja Kottmann

CRO Dr. med. Tanja Kottmann

kontakt@cro-kottmann.de02381 972090

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026